Probing the combination of erlotinib hydrochloride, an anticancer drug, and human serum albumin: Spectroscopic, molecular docking, and molecular dynamic analyses
Luminescence · 2023
DOI: 10.1002/bio.4506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Luminescence, 2023. Verfasst von Somaye Shahraki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Zabol, Zabol, Iran. Hauptthemen laut MEDLINE: Serum Albumin, Human, Antineoplastic Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: University of Zabol.
Abstract (Originalsprache)
Human serum albumin (HSA) is a globular and monomeric protein in plasma that transports many drugs and compounds. Binding of some drugs to HSA can lead to changes in its stability and biological function. We investigated the binding interactions between erlotinib hydrochloride (Erlo) and HSA. Erlo is used to treat lung, pancreatic, and some other cancers. Experimental data showed that the fluorescence emission of the protein was quenched by Erlo using a static quenching mechanism. The calculation of the binding constant, K b (1.57 × 10 5 M −1 at 300 K), confirmed the existence of a moderate binding interaction between Erlo and HSA. The interaction was enthalpy driven, spontaneous, and exothermic. The calculated thermodynamic parameters in agreement with simulation and molecular docking data showed that van der Waals and hydrogen bond forces played an important role in the interaction process. Molecular docking results indicated that Erlo has more affinity to bind to subdomain IIA (site I) of HSA. Molecular dynamics simulation analysis showed that the protein is stable in the presence of Erlo under simulation conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Zabol, Zabol, Iran.
ORCID-Profile: Somaye Shahraki
Förderung
- University of Zabol
Zitieren
APA
Shahraki, S., Razmara, Z., Delarami, H. S., & Poorsargol, M. (2023). Probing the combination of erlotinib hydrochloride, an anticancer drug, and human serum albumin: Spectroscopic, molecular docking, and molecular dynamic analyses. Luminescence. https://doi.org/10.1002/bio.4506
Vancouver
Shahraki S, Razmara Z, Delarami HS, Poorsargol M. Probing the combination of erlotinib hydrochloride, an anticancer drug, and human serum albumin: Spectroscopic, molecular docking, and molecular dynamic analyses. Luminescence. 2023. doi:10.1002/bio.4506
BibTeX
@article{Shahraki2023,
author = {Shahraki, Somaye and Razmara, Zohreh and Delarami, Hojat Samareh and Poorsargol, Mahdiye},
title = {Probing the combination of erlotinib hydrochloride, an anticancer drug, and human serum albumin: Spectroscopic, molecular docking, and molecular dynamic analyses},
journal = {Luminescence},
year = {2023},
doi = {10.1002/bio.4506}
}
EUVIMED